Gut microbiota and gastrointestinal health: Current concepts and future directions

Neurogastroenterology and Motility

Volumn 25, Issue 1, 2013, Pages 4-15

  Aziz, Q ^a   Dore J ^b   Emmanuel, A ^c   Guarner, F ^d   Quigley, E M M ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CEMAGREF   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bragut axis; Functional; Gut; Microbiota

Indexed keywords

PROBIOTIC AGENT;

BRAIN; CELIAC DISEASE; CLOSTRIDIUM DIFFICILE; CROHN DISEASE; DIET; GASTROINTESTINAL DISEASE; HEALTH CARE; HUMAN; ILEITIS; INTESTINE FLORA; IRRITABLE COLON; METAGENOMICS; MICROFLORA; NOCICEPTION; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NUTRITION; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ULCERATIVE COLITIS;

GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; METAGENOME;

EID: 84871642532     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12046     Document Type: Review

References (94)

1. Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854-9.
2. Tap J, Mondot S, Levenez F et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009; 11: 2574-84.
3. QJ, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
4. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J ClNutr 1999; 69: 1035S-45S.
5. Vanhoutte T, Huys G, Brandt E, Swings J. Temporal stability analysis of the microbiota human feces by denaturing gradient gel electrophoresis using universal and group-specific 16S rRNA gene primers. FEMS Microbiol Ecol 2004; 48: 437-46.
6. Seksik P, Rigottier-Gois L, Gramet G et al. Alterations of the dominant faecal bacterial groups patients with Crohn's disease of the colon. Gut 2003; 52: 237-42.
7. Seksik P, Sokol H, Lepage P et al. Review article: the role of bacteria onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24(Suppl. 3): 11-8.
8. Sokol H, Lepage P, Seksik P, Dore J, Marteau P. Molecular comparison of dominant microbiota associated with injured versus healthy mucosa ulcerative colitis. Gut 2007; 56: 152-4.
9. Penders J, Stobberingh EE, Van den Brandt PA, et al. The role of intestinal microbiota the development of atopic disorders. Allergy 2007; 62: 1223-36.
10. Marteau P. Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? Gut 2006; 55: 1692-3.
11. Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32.
12. Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012; 6: 312-22.
13. Simrén M, Barbara G, Flint HJ et al. Intestinal microbiota functional bowel disorders: a Rome foundation report. Gut 2012. (press)
14. Suau A, Bonnet R, Sutren M et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species withthe human gut. Appl Environ Microbiol 1999; 65: 4799-807.
15. Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80.
16. Nicholson JK, Holmes E, Kinross J et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-7.
17. Wu GD, Chen J, Hoffmann C et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-8.
18. Claesson MJ, Cusack S, O'Sullivan O et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011; 108(Suppl. 1): 4586-91.
19. Claesson MJ, Jeffery IB, Conde S et al. Gut microbiota composition correlates with diet and health the elderly. Nature 2012; 488: 178-84.
20. De La Cochetiere MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Dore J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J ClMicrobiol 2005; 43: 5588-92.
21. Guarnier F. The enteric microbiota. Granger DN, Granger J, Morgan & Claypool Life Sciences, eds. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease. USA: Morgan&Clay pool Life Sciences Publishers, 2011: 1-77.
22. Delzenne NM, Neyrinck AM, Backhed F, Cani PD. Targeting gut microbiota obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011; 7: 639-46.
23. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-23.
24. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota health and disease. Physiol Rev 2010; 90: 859-904.
25. Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gahumans. Future Microbiol 2012; 7: 91-109.
26. Louis P, O'Byrne CP. Life the gut: microbial responses to stress the gastrointestinal tract. Sci Prog 2010; 93(Pt 1): 7-36.
27. Guarnier F, Bourdet-Sicard R, Brandtzaeg P et al. Mechanisms of disease: the hygiene hypothesis revisited. Nat ClPract Gastroenterol Hepatol 2006; 3: 275-84.
28. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation the intestine. Gastroenterology 2011; 140: 1768-75.
29. Konieczna P, Groeger D, Ziegler M et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012; 61: 354-66.
30. Van Nimwegen FA, Penders J, Stobberingh EE et al. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy ClImmunol 2011; 128: 948-55.
31. Quigley EM. Prebiotics and probiotics; modifying and mining the microbiota. Pharmacol Res 2010; 61: 213-8.
32. Rowland IR. The role of the gastrointestinal microbiota colorectal cancer. Curr Pharm Des 2009; 15: 1524-7.
33. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008; 3: 563-78.
34. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003; 349: 2136-46.
35. Bolino CM, Bercik P. Pathogenic factors involved the development of irritable bowel syndrome: focus on a microbial role. Infect Dis ClNorth Am 2010; 24: 961-75.
36. Rajilic-Stojanovic M, Biagi E, Heilig HG et al. Global and deep molecular analysis of microbiota signatures fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-801.
37. Jeffery IB, O'Toole PW, Öhman L et al. An irritable bowel syndrome subtype defined by species-specific alterations faecal microbiota. Gut 2012; 61: 997-1006.
38. Ghoshal UC, Shukla R, Ghoshal U et al. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012. (press).
39. Azpiroz F, Malagelada JR. The pathogenesis of bloating and visible distension irritable bowel syndrome Gastroenterol. ClNorth Am 2005; 34: 257-69.
40. Vanner S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut 2008; 57: 1315-21.
41. Koshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53: 1443-54.
42. Langhorst J. Elevated human beta-defensin-2 levels indicate an ctivation of the innate immune system patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-10.
43. Brint EK, MacSharry J, Fannig A, Shanahan F, Quigley EM. Differential expression of toll like receptors patients with Irritable Bowel. Am J Gastroenterol 2011;106: 329-36. Mediators: Gut 2002; 51(Suppl. 1): i19-23.
44. O'Mahony L, Mccarthy J, Kelly P et al. Lactobacillus and Bifidobac-terium irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
45. Liebregts T, Adam B, Bredack C et al. Immuneactivation patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
46. Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic- pituitary-gut axis dysregulation irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-11.
47. Quigley EM. Gut microbiota and the role of probiotics therapy. Curr OpPharmacol 2011; 11: 593-603.
48. Quigley EM. The enteric microbiota the pathogenesis and management of constipation. Best Pract Res ClGastroenterol 2011; 25: 119-26.
49. Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol ClNorth Am 2011; 40: 207-22.
50. Pimentel M, Lembo A, Chey WD et al. Rifaximtherapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
51. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms irritable bowel syndrome. Alim Pharmacol and Ther 2009; 29: 508-18.
52. Sartor RB. Microbial influences inflammatory bowel diseases. Gastroenterology 2008; 134: 577-94.
53. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J ClInvest 2007; 117: 514-21.
54. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
55. Franchimont D, Vermeire S, El Housni H et al. Deficient host-bacteria interactions inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53: 987-92.
56. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases childhood. Gut 2011; 60: 49-54.
57. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104: 13780-5.
58. Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of faecal microbiota Crohn's disease revea]led by a metagenomic approach. Gut 2006; 55: 205-11.
59. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008; 105: 16731-6.
60. Llopis M, AntolM, Carol M et al. Lactobacillus casei downregulates commensals' inflammatory signals Crohn's disease mucosa. Inflamm Bowel Dis 2009; 15: 275-83.
61. CaAM, Karpa KD. Clinical utility of probiotics inflammatory bowel disease. Altern Ther Health Med 2011; 17: 72-9.
62. Kau AL, Ahern PP, GriffNW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474: 327-36.
63. De Filippo C, Cavalieri D, Di Paola M et al. Impact of diet shaping gut microbiota revealed by a comparative study children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010; 107: 14691-6.
64. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011; 12: 5-9.
65. Waldram A, Holmes E, Wang Y et al. Top-down systems biology modeling of host metabotype-microbiome associations obese rodents. J Proteome Res 2009; 8: 2361-75.
66. Backhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011; 58(Suppl. 2): 44-52.
67. Greiner T, Backhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 2011; 22: 117-23.
68. Kootte RS, Vrieze A, Holleman F et al. The therapeutic potential of manipulating gut microbiota obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-20.
69. Raybould HE. Gut microbiota, epithelial function and derangements obesity. J Physiol 2012; 590: 441-6.
70. Ley RE. Obesity and the human microbiome. Curr OpGastroenterol 2010; 26: 5-11.
71. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-23.
72. Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010; 268: 320-8.
73. Furet JP, Kong LC, Tap J et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049-57.
74. Abu-Shanab A, Quigley EM. The role of the gut microbiota nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 691-701.
75. Chassard C, Dapoigny M, Scott KP et al. Functional dysbiosis withthe gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-38.
76. Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol 2007; 56: 1669-74.
77. Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis ClNorth Am 2010; 24: 943-59, viii-ix.
78. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306-14.
79. Cryan JF, O'Mahony SM. The microbiome-gut-braaxis: from bowel to behavior. Neurogastroenterol Motil 2011; 23: 187-92.
80. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication health and disease. Front Physiol 2011; 2: 94.
81. Bravo JA, Forsythe P, Chew MV et al. Ingestion of Lactobacillus straregulates emotional behavior and central GABA receptor expression a mouse via the vagus nerve. Proc Natl Acad Sci U S A 2011; 108: 16050-5.
82. Sudo N, Chida Y, Aiba Y et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response mice. J Physiol 2004; 1: 263-75.
83. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) healthy human volunteers. Gut Microbes 2011; 2: 256-61.
84. Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal paand induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-7.
85. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system normal gastrointestinal function and disease. Gastroenterology 2009; 136: 2003-14.
86. Eutamene H, Bueno L. Role of probiotics correcting abnormalities of colonic flora induced by stress. Gut 2007; 56: 1495-7.
87. Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change germ-free mice. Neurogastroenterol Motil 2011; 23: 255-64, e119.
88. McLean PG, Bergonzelli GE, Collins SM, Bercik P. Targeting the microbiota-gut-braaxis to modulate behavior: which bacterial strawill translate best to humans? Proc Natl Acad Sci U S A 2012; 109: E174.
89. Huertas-Caballos A, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pa(RAP) and irritable bowel syndrome childhood. Cochrane Database Syst Rev 2008; 23: CD0030019.
90. McFarland LV, DublS. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-61.
91. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-80.
92. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15.
93. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-49.
94. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders childhood. Aliment Pharmacol Ther 2011; 33: 1302-10.